All articles by Phillip Broadwith – Page 7
-
BusinessAvantor to buy VWR for $6.4bn
Deal continues trend of consolidation in laboratory supplies sector
-
BusinessBP to sell Chinese joint venture stake to Sinopec
Oil giant retains significant investment in China, but is shifting focus
-
BusinessChina approves BMS’s hepatitis C drugs
Combination is first all-oral treatment in China, where Gilead’s Sovaldi is not yet approved
-
OpinionBuilding business across borders
Internationality is here to stay. Companies need to capitalise on it
-
BusinessFresenius to buy Akorn and Merck KGaA’s biosimilars
Deals give Fresenius entry into rapidly growing biological drugs market
-
BusinessJob cuts at Amgen, Takeda and Vertex
Takeda reorganising following Ariad takeover, while Amgen and Vertex move staff to Cambridge and San Francisco hubs
-
BusinessAnalytical data heads to the cloud
Many manufacturers were launching software instead of instruments at Pittcon
-
BusinessExpanding precision medicine beyond cancer
Exclusive interview with Koustubh Ranade, vice president of R&D at MedImmune
-
BusinessPacBio sues Oxford Nanopore for patent infringement
Firms spar over single-molecule gene sequencing technology
-
BusinessJ&J to close Scottish medical device plant
Up to 400 positions affected as Ethicon subsidiary leaves Livingston
-
OpinionCollaboration and competition can both stimulate innovation
Diverse approaches suit different goals
-
BusinessAllergan to buy fat-freezing firm Zeltiq
$2.5bn deal adds to firm’s cosmetic and aesthetic treatments
-
BusinessDaiichi Sankyo to close R&D sites in India and Japan
Closures are part of an ongoing reorganisation aimed at increasing productivity
-
BusinessSabic takes control of Shell petrochemicals joint venture
$820m sale of Saudi Arabian plants continues Shell’s global reorganisation programme
-
OpinionHow much is your chief executive worth?
The executive pay and equality debate is here to stay
-
BusinessLilly buys CoLucid for migraine drugs
US firm also laying off 485 sales staff after Alzheimer’s drug failure
-
BusinessMerck & Co settles cancer antibody patent dispute
US firm will pay Bristol-Myers Squibb and Ono $625m plus royalties on future sales of immunotherapy
-
BusinessTeva hit with fines and patent loss
Double whammy as firm settles subsidiary pay-for-delay suit and courts invalidate patents on multiple sclerosis drug
-
BusinessJ&J to buy Actelion for $30bn
Actelion’s R&D will spin out as a new company, while Janssen will take on in-market and late-stage medicines
-
BusinessBiogen pays $1.25bn to protect multiple sclerosis drug sales
Agreement with Forward Pharma gives Biogen license to keep selling blockbuster Tecfidera